Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.63 |
| ▸ | TP53 | P04637 | 4/20 | 0.63 |
| ▸ | THRB | P10828 | 1/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.59 |
| ▸ | NPC1 | O15118 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.59 |
| ▸ | RAB9A | P51151 | 1/20 | 0.59 |
| ▸ | IMPDH2 | P12268 | 3/20 | 0.55 |
| ▸ | KDR | P35968 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4034654 | 1.00 | MAPT (0.63) | MAPTTP53THRBSMN1; SMN2KDM4E | |
| SCHEMBL2240335 | 0.92 | NPC1 (0.70) | MAPTTP53THRBSMN1; SMN2KDM4E | |
| SCHEMBL3953026 | 0.89 | MAPT (0.62) | MAPTTP53THRBSMN1; SMN2KDM4E | |
| SCHEMBL3953020 | 0.89 | MAPT (0.62) | MAPTTP53THRBSMN1; SMN2KDM4E | |
| SCHEMBL3716583 | 0.84 | TP53 (0.61) | MAPTTP53THRBSMN1; SMN2KDM4E | |
| SCHEMBL2245123 | 0.83 | KDM4E (0.59) | MAPTTP53THRBSMN1; SMN2KDM4E | |
| SCHEMBL2246997 | 0.83 | NPC1 (0.73) | MAPTTP53THRBSMN1; SMN2KDM4E | |
| SCHEMBL2247720 | 0.82 | MAPT (0.78) | MAPTTP53THRBSMN1; SMN2KDM4E | |
| SCHEMBL2242964 | 0.81 | SMN1; SMN2 (0.74) | MAPTTP53THRBSMN1; SMN2KDM4E | |
| SCHEMBL2245043 | 0.81 | CASP3 (0.72) | MAPTTP53THRBSMN1; SMN2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009021750-A2 | TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | SUMMIT CORPORATION PLC (GB) | 2009-02-19 | — | — | WO | disclosed |